Basics |
Amgen Inc.
Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.
|
IPO Date: |
January 2, 1990 |
Sector: |
Healthcare |
Industry: |
Biotech |
Market Cap: |
$146.15B |
Activated in VL: |
True |
Average Daily Range |
Avg Daily Range: |
$1.36 | 0.99%
|
Avg Daily Range (30 D): |
$4.61 | 1.60%
|
Avg Daily Range (90 D): |
$3.63 | 1.25%
|
Institutional Daily Volume |
Avg Daily Volume: |
4.86M |
Avg Daily Volume (30 D): |
2.35M |
Avg Daily Volume (90 D): |
2.3M |
Trade Size |
Avg Trade Size (Sh.): |
135 |
Avg Trade Size (Sh.) (30 D): |
38 |
Avg Trade Size (Sh.) (90 D): |
41 |
Institutional Trades |
Total Inst.Trades: |
112,694 |
Avg Inst. Trade: |
$6.14M |
Avg Inst. Trade (30 D): |
$31.92M |
Avg Inst. Trade (90 D): |
$32.23M |
Avg Inst. Trade Volume: |
.05M |
Avg Inst. Trades (Per Day): |
20 |
Market Closing Trades |
Avg Closing Trade: |
$63.89M |
Avg Closing Trade (30 D): |
$163.91M |
Avg Closing Trade (90 D): |
$170.5M |
Avg Closing Volume: |
386.12K |
|
|
|
|
Financials |
|
TTM |
Q1 2025 |
Q3 2024 |
Basic EPS
|
|
$3.22
|
$5.27
|
Diluted EPS
|
|
$3.2
|
$5.22
|
Revenue
|
$
|
$ 8.15B
|
$ 8.5B
|
Gross Profit
|
$
|
$ 5.18B
|
$ 5.19B
|
Net Income / Loss
|
$
|
$ 1.73B
|
$ 2.83B
|
Operating Income / Loss
|
$
|
$ 1.18B
|
$ 2.05B
|
Cost of Revenue
|
$
|
$ 2.97B
|
$ 3.31B
|
Net Cash Flow
|
$
|
$ -3163M
|
$ -290M
|
PE Ratio
|
|
|
|
|